Based on these findings, under the condition that this combination is safe and feasible, we see clinical potential in combining midostaurin, venetoclax and Eht1864 as a novel therapeutic strategy to treat FLT3-mutant AML patients (Fig. 6b). Here, FLT3 is linked to acute myeloid leukemia.